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Introduction. It wasreported that25-hydroxyvitamin Dlevel wasindependently associatedwithanemiain chronic kidney diseases,
buttherelationbetween vitaminDandanemiaindiabetes mellitusisnotstillcertain. Weanalyzedtherelationbetween plasma25-
hydroxyvitaminDlevelandhemoglobinconcentration.Materials andMethods.Across-sectionalstudyinmalepatientswithtype2
diabetes was performed. Correlation coeﬃcients and standardized partial regression coeﬃcient for the hemoglobin concentration
were evaluated. Results. Hemoglobin concentration was positively correlated with body mass index, HbA1c, estimated glomerular
ﬁltration rate, cholinesterase, and 25-hydroxyvitamin D level and negatively correlated with age, duration of diabetes mellitus,
serum creatinine, and urinary albumin creatinine ratio. Multiple regression analysis revealed the independent relation of 25-
hydroxyvitaminD to hemoglobinconcentration.Conclusions. Plasmacirculatingformof vitaminD issigniﬁcantlyassociatedwith
hemoglobin concentration in diabetes mellitus independent of the clinical markers for kidney function or nutrition.
1.Introduction
Anemia is a common complication of chronic kidney disease
(CKD). In diabetes mellitus, anemia develops earlier and is
more severe than in patients with renal impairment with
other causes [1, 2]. Anemia in diabetes mellitus is known
to be a risk factor for the development and progression of
micro-andmacrovascular complicationsofdiabetesmellitus
as well as increased mortality independent of the presence or
severity of diabetic nephropathy [3]. A reduced hemoglobin
concentration, even within the normal range, is associated
with an increased risk of end-stage renal disease (ESRD)
and death [4]. The main cause of anemia in diabetes is
suspected to be reduced erythropoietin production relative
to the degree of anemia, and some researchers observed
microscopic injury of the renal tubulointerstitium, where
erythropoietinisproduced,indiabeticsubjects,eveninthose
with no sign of diabetic glomerular injury [5, 6]. On the
other hand, there was another report which reported that
plasma erythropoietin level was increased, but the expected
reticulocyteresponse wasdecreasedindiabeticsubjectswith-
out nephropathy [7]. So the exact reason for anemia in
diabetes is not still certain.
Vitamin D (VD) is prohormone important for serum
calcium and phosphorus homeostasis, which is necessary
for neuromuscular function and optimal skeletal health. It
can be obtained from the diet or made in the skin after
exposure to ultraviolet B radiation from the sun. VD is
converted to its major circulating form, 25-hydroxyvitamin
D (25(OH)D), by the liver, then to an activated form,
1,25-dihydroxyvitamin D (1,25(OH)2D ) ,b yt h ek i d n e y .T h e
plasma 25(OH)D level is quite stable over several days or2 International Journal of Endocrinology
weeks and typically ﬂuctuates with VD intake and UVB
exposure. It directly reﬂects VD reserve in the body. Both
25(OH)D and 1,25(OH)2D in plasma are reduced during
the early stage of CKD [8, 9], and they are independently
associated with decreased hemoglobin level and anemia in
CKD [9]. The reason why the plasma level of 25(OH)D
is decreased in the subjects with kidney dysfunction is not
stillcertain,butdiabetesmellituswasrelated tothedecreased
plasma levels of both 25(OH)D and 1,25(OH)2D[ 8].
Previous studies have suggested improved control of anemia
in dialysis patients treated with active forms of VD or
nutritional VD precursors [10–13]. So VD deﬁciency may
directly relate to anemia.
Wespeculatedthatthereisarelationshipbetweenanemia
of diabetes mellitus and VD status and performed a cross-
sectional study which evaluated the plasma level of VD in
patients with type 2 diabetes mellitus.
2.Subjectsand Methods
The studywas conductedin accordance with the Declaration
of Helsinki, and the protocol was approved by the Ethical
Committee of the hospital. Patients with hematological
disorders, active inﬂammatory or infectious diseases, liver
c i r r h o s i s ,o rm a l i gn a n td i s e a s e sa sw e l la sp a t i e n t sw i t ha c t i v e
gastrointestinal diseases were not enrolled in this study.
Patients whose mean corpuscular volume values were less
than80ﬂwerealsonotenrolledtoexcludetheirondeﬁciency
a n e m i ab e c a u s ew ea i m e dt oev a l u a t et h en o rm o c yt i ca n e m i a
which was basically related to diabetes mellitus. Patients
receiving VD or erythropoiesis-stimulating agents (ESAs)
were excluded from the analysis. Subjects who were under
hemodialysis or peritoneal dialysis treatment were also ex-
cluded because they were receiving VD or ESAs at a high
rate. As the number of female subjects who consented
to the study was small, we analyzed the data only in
male subjects. We eventually examined 106 male subjects
with type 2 diabetes mellitus who attended the outpatient
clinic of Saiseikai Central Hospital between September 2009
and February 2010. Saiseikai Central Hospital is one of
the biggest diabetic centers in Japan. So the considerable
percentageofthepatientsvisitingtherewerereferredsubjects
because of diﬃcult diabetic control although the health
insurance in Japan permitted any person to access freely to
any facilities. And, to evaluate the eﬀect of advanced stage of
diabetic nephropathy, we actively enrolled the subjects with
nephropathy to make equivalent the number of the subjects
among each clinical stage of diabetic nephropathy.
After obtaining written informed consent, bloodsamples
in an overnight fasting state were drawn in the usual
outpatient clinic. Routine blood analysis was performed at
the hospital laboratory immediately after blood sampling.
After centrifugation, a part of the plasma was preserved
at −80◦C until further analysis. Serum fasting glucose,
total cholesterol, HDL cholesterol, triglyceride, serum
creatinine levels, and several other biochemical assays were
performed with autoanalyzers. We also evaluated plasma
cholinesterase as a clinical marker of nutrition status [14]
by the enzymatic method using 5-methyl-2-thenoylthiocho-
lineiodide. HbA1c level was determined by high-perform-
ance liquid chroma tography (HPLC: Arkray Inc., Kyoto,
Japan) according to the method of the Japanese Diabetes
Society (JDS) units. The value for HbA1c (%) is estimated
as a National Glycohemoglobin Standardization Program
(NGSP) equivalent value (%) calculated by the formula
HbA1c (%) = HbA1c (JDS) (%) + 0.4%, considering the
relational expression of HbA1c (JDS) (%) measured by the
previous Japanese standard substance and measurement
methods and HbA1c (NGSP) [15]. Microalbuminuria was
deﬁned as an albumin creatinine ratio (ACR) of 30 to
300mg/gCr and macroalbuminuria as ACR of more than
300mg/gCr in spot urinalysis. Estimated glomerular ﬁl-
tration rate (eGFR) (mL/min/1.73m2) was calculated as
194 × Cr−1.094× Age−0.287 using the equation provided by
the Japanese Society of Nephrology [16]. Plasma levels of
25(OH)D and vitamin D binding protein (DBP) were
measured by ELISA using 25(OH)-Vitamin D direct ELISA
Kit (Immundiagnostik AG, Bensheim, Germany) and,
ELISA Kit Vitamin D binding protein (Immundiagnostik
AG, Bensheim, Germany), respectively, according to the
manufacture manual at the laboratory of the National In-
stitute of Infectious Diseases.
All subjects underwent funduscopic examination by
trained ophthalmologists. Clinical stages of diabetic retino-
pathy were classiﬁed as none, background retinopathy, and
more advanced stages or previous history of photocoagu-
lation. Clinical stages of diabetic nephropathy were clas-
siﬁed as none, microalbuminuria, macroalbuminuria, and
chronic renal failure, which was deﬁned as eGFR less than
30mL/min/1.73m2. Past history of cardiovascular disease
was determined by checking medical records or detailed
medical interview. Prior history of myocardial infarction,
coronary intervention, ischemic stroke, or peripheral artery
disease was regarded as a history of CVD.
Continuous variables are expressed as mean ± SD.
Correlation coeﬃcients were analyzed by Spearman’s rank
test. Multiple regression analysis with compulsory input
was performed to evaluate the independent contribution
to hemoglobin concentration. P<. 05 was considered
statistically signiﬁcant. All analyses were performed using
SPSS 18.0 statistical software (SPSS Inc., Chicago, Ill, USA).
3.Results
Thebaselinecharacteristicsofthestudysubjectsareshownin
Table 1. All patients were Japanese. Mean age of the patients
was 64.5 ± 12.2 years old, and BMI was 25.2 ± 4.4. Mean
HbA1c was 7.8 ± 1.6% with average 18-year duration of
the disease. As a consequence of our enrollment policy, the
proportions of the advanced stages of diabetic nephropathy
were much higher than general diabetic population (renal
failure: 22.6%, macroalbuminuria: 27.4%, microalbumin-
uria: 33.0%, none: 17.0%). Mean value of plasma 25(OH)D
was 27.5 ± 12.1ng/mL.
The results of Spearman’s rank correlation coeﬃcients
with hemoglobin concentration are shown in Table 2.B M I
(ρ = 0.441, P<. 01), HbA1c (ρ = 0.340, P<. 01),
eGFR (ρ = 0.550, P<. 01), cholinesterase (ρ = 0.580,International Journal of Endocrinology 3
Table 1: Clinical characteristics of subjects. Continuous variables
are expressed as mean ± SD.
Age (y/o) 64.5 ± 12.2
BMI 25.2 ± 4.4
Duration of diabetes mellitus (year) 18.1 ± 11.1
Fasting plasma glucose (mmol/L) 9.7 ± 3.0
HbA1c (%) 7.8 ± 1.6
Total cholesterol (mmol/L) 4.76 ± 0.78
HDL cholesterol (mmol/L) 1.34 ± 0.35
Triglyceride (mmol/L) 1.85 ± 2.05
Estimated GFR (mL/min/1.73m2) 54.5 ± 26.8
Albumin creatinine ratio (mg/g Cr) 852.7 ± 1426
hs CRP (mg/dL) 0.14 ± 0.40
White blood cell count (mm3) 7064 ± 1954
Red blood cell count (×104/mm3) 438 ± 64.8
Hemoglobin (g/L) 140 ± 19
Hematocrit (%) 40.3 ± 5.3
Mean corpuscular volume (ﬂ) 92.2 ± 4.2
25-hydroxyvitamin D (ng/mL) 27.5 ± 12.1
Vitamin D binding protein (μg/mL) 316 ± 38.4
Diabetic nephropathy
(none/microalbuminuria/
macroalbuminuria/renal failure)
18/35/29/24
Diabetic retinopathy
(none/background/more advanced stage
or prior photocoagulation)
43/44/19
History of cardiovascular disease
(none/positive) 70/36
Percentage of smoker (%) 29.2
P<. 01), and 25(OH)D (ρ = 0.269, P<. 01) were positively
correlatedwithhemoglobinconcentration.Age(ρ =− 0.433,
P<. 01),durationofdiabetesmellitus(ρ =− 0.366,P<. 01),
serum creatinine (ρ =− 0.506, P<. 01), and ACR (ρ =
−0.453,P<. 01)were negatively correlated with hemoglobin
concentration.
In multiple regression analysis, 25(OH)D was signiﬁ-
cantly associated with hemoglobin concentration indepen-
dent of ACR, eGFR, BMI, and cholinesterase as well as age
(Table 3).
4.Discussion
Our study demonstrated that plasma 25(OH)D level was
signiﬁcantly associated with hemoglobin concentration in
male subjects with type 2 diabetics. Multiple regression anal-
ysis showed that its relation to hemoglobin concentration
was independent of the clinical markers of both kidney
function and nutrition. As it is reported that a reduced
hemoglobinconcentrationis associated with the progression
of the diabetic complication and the poorer outcome, the
relation between a hemoglobin concentration and 25(OH)D
level may be involved in the pathophysiology of the disease,
even if it is direct or indirect, and the explication of this
relationmaygivesomecluesforthenewtargetofthetherapy.
Table 2: Correlation of hemoglobin concentration with clinical
covariates. Spearman’s rank test was performed. P<. 05 was
considered statistically signiﬁcant. “n.s.” denotes “not signiﬁcant.”
Statistical analyses were performed using SPSS 18.0 statistical
software.
Correlation
coeﬃcients P value
Age −0.433 <.01
BMI 0.441 <.01
Duration of diabetes
mellitus
−0.366 <.01
Fasting plasma glucose 0.151 n.s.
HbA1c (%) 0.340 <.01
Total cholesterol 0.146 n.s.
Triglyceride 0.190 n.s.
Serum creatinine −0.506 <.01
eGFR 0.550 <.01
Albumin creatinine ratio −0.453 <.01
cholinesterase 0.580 <.01
High sensitive C reactive
protein
−0.058 n.s.
25-hydroxyvitamin D 0.269 <.01
Vitamin D binding protein 0.112 n.s.
Table 3: Multiple regression analysis for hemoglobin concen-
tration. Beta is the standardized partial regression coeﬃcient of
multiple regression analysis.“n.s.” denotes “not signiﬁcant.”
R2 0.58
Variables Beta P value
Age −0.105 n.s.
BMI 0.208 .02
HbA1c 0.011 n.s.
ACR −0.304 <.01
eGFR 0.231 .02
Cholinesterase 0.179 n.s.
25-hydroxyvitamin D 0.188 .02
Although it was reported that plasma 25(OH)D was
decreased in CKD, particularly in diabetic subjects [8], the
exact reason was not elucidated. Malnutrition or decreased
intake of VD was one of the candidates for explanation,
but, from the nutrition status presumed by baseline clinical
characteristicssuchasBMI,cholinesterase,orlipidproﬁles,it
wasunlikelyinourstudy.Inadditiontothat,thehemoglobin
concentration was signiﬁcantly correlated with 25(OH)D in
multipleregression analysis independentofclinicalnutrition
markers such as BMI and cholinesterase. Although we
did not check the daily VD intake, we supposed that the
possibility of low VD intake was not high.
As25(OH)Disconvertedtoitsactive form, 1,25(OH)2D,
in the renal tubulointerstitium, our results may have been
induced by early tubulointerstitial damage in diabetic
patients, which has recently been suggested by several
researchers [5, 6] .I nf a c t ,S i n g he ta l .r e p o r t e dt h a tb o t h
erythropoietin and 1,25(OH)2D levels were lower in diabetic4 International Journal of Endocrinology
patients without overt nephropathy than in control subjects,
although their relations with conventional clinical markers
for renal tubulointerstitial injury like urinary NAG were not
strong [17]. If that were the case, plasma erythropoietin and
1,25(OH)2D level might have been decreased in our cases,
but it is only a speculation because we did not check them.
However, in this study, plasma 25(OH)D was associated
with hemoglobin concentration independent of the clinical
markers of kidney dysfunction. It has been reported that
plasma erythropoietin level was increased, but the expected
reticulocyte response was decreased in diabetic subjects
without nephropathy [7]. In patients on hemodialysis, it
was recently reported that plasma 25(OH)D concentration
was associated with both hemoglobin level and erythropoi-
etin resistance [18]. So the association between VD and
hemoglobin concentration may be explained by a mecha-
nism except for erythropoietin reduction.
As another possible explanation, it has been reported
that 1,25(OH)2Dh a sad i r e c te ﬀect on erythropoiesis [19,
20]. Previous studies have suggested improved control of
anemia in dialysis patients treated with active forms of
VD or nutritional VD precursors [10–13]. Moreover, many
tissues possess CYP27B1 and are able to activate VD [21].
Recent ﬁndings indicated that VD is activated outside the
kidney [22]. It was reported that hematons (the buﬀyc o a t
of bone marrow containing erythroid precursors, ﬁbrob-
last, endothelial cells, lipid laden cells, and macrophages)
have been demonstrated to contain signiﬁcantly higher
concentrations of 25(OH)D and 1,25(OH)2Dl e v e l st h a n
bone marrow plasma [22]. High local concentrations of
1,25(OH)2D in hematopoietic tissues may directly activate
erythroid precursor cells in a paracrine fashion through the
local activation of 25(OH)D in bone marrow though it is
only a speculation.
There are some limitations to this study. As this was a
cross-sectional study, it is not possible to determine a causal
relationship between VD and hemoglobin. The age of our
study subjects was so varied that their dietary intake and
physical activities might diﬀe r .I na d d i t i o n ,w ed on o th a v e
data on plasma erythropoietin and reticulocyte count, as
well as clinical markers of renal tubulointerstitial damage,
so we could not analyze the relation among VD and these
markers. As our patients were Japanese subjects with long-
standing type 2 diabetes mellitus, it is not clear whether
we can extend our results to the other populations. As the
other limitation, we did not evaluate the plasma testosterone
level which might inﬂuence the hemoglobin concentrations
intheseoldermales.Lastly,thesamplesizewassmall, andthe
samples were not recruited in a random manner, so selection
biascannot beexcluded.Furtherstudieswith largernumbers
of participants are needed to elucidate the relation between
VD and the mechanism of anemia.
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